Navigation Links
Jazz Pharmaceuticals Announces Third Quarter 2013 Financial Results
Date:11/5/2013

ivate Securities Litigation Reform Act of 1995This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' future financial results, the company's growth strategy and potential, 2013 financial guidance and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with maintaining and increasing sales of and revenue from Xyrem, such as the potential introduction of generic competition and changed or increased regulatory restrictions on or requirements with respect to Xyrem, as well as similar risks related to effectively commercializing the company's other marketed products, including Erwinaze and Prialt; protecting and expanding the company's intellectual property rights; obtaining appropriate pricing and reimbursement for the company's products in an increasingly challenging environment; ongoing regulation and oversight by U.S. and non-U.S. regulatory agencies; dependence on key customers and sole source suppliers, including the risk that the company may not be able to supply sufficient product to meet demand; the difficulty and uncertainty of pharmaceutical product development, including the timing thereof and the uncertainty of clinical success and regulatory approval; the company's ability to identify and acquire, in-license or develop additional products or product candidates to grow its business; and possible restrictions on the company's ability and flexibility to pursue certain future opportunities as a result of its substantial outstanding debt obligations; as well as risks related to future opportunities and plans, in
'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
2. Aquavit Pharmaceuticals Adds New Advanced Drug Delivery Technology to Product Portfolio
3. Jazz Pharmaceuticals to Present at the 2013 Credit Suisse Healthcare Conference on November 12
4. Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange
5. Actinium Pharmaceuticals to Host Corporate Update and Virtual Roadshow Conference Call on November 11
6. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
7. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7
8. Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
9. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
10. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013
11. Cumberland Pharmaceuticals To Announce Third Quarter 2013 Financial Results On November 5, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Ga., Feb. 26, 2015  MiMedx Group, Inc. (NASDAQ: ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental ... the fourth quarter and full year ended December 31, ... 2014 Highlights , Full Year 2014 ...
(Date:2/26/2015)... 26, 2015  PDL BioPharma, Inc. (PDL or the Company) ... will hold its annual meeting of stockholders on Thursday, May ... of record on April 2, 2015. The meeting will take ... Village, Nevada . About PDL BioPharma PDL ... its Queen et al. patents, license agreements with various biotechnology ...
(Date:2/26/2015)... MnM Conferences is pleased to ... place on the 27 - 28 April 2015 and will ... . Leading academics, scientists and business development ... world will be travelling to the Nanotechnologies in Drug ... capitalists and other financiers looking to invest in their ...
Breaking Medicine Technology:MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 2MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 3MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 4MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 5MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 6MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 7MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 8MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 9MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 10MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 11MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 12MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 13MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 14MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 15MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 16MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 17MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit 18PDL BioPharma to Hold Annual Meeting of Stockholders on May 28, 2015 2MnM Conferences Announces Their Inaugural Congress - Nanotechnologies in Drug Delivery 2MnM Conferences Announces Their Inaugural Congress - Nanotechnologies in Drug Delivery 3
... May 16, 2011 For the second year in a row, ... recognized Eveo Communication Group ( www.eveo.com ) as ... advanced another front in the annual A d ... 25 Healthcare Agency list for the first time. (Photo: ...
... May 16, 2011 Telik, Inc. (Nasdaq: TELK ... March 31, 2011.  The net loss for the quarter ended ... a net loss of $5.3 million, or $0.10 per share, for ... development expenses (R&D) in the first quarter of 2011 were ...
Cached Medicine Technology:Eveo Ranked #1 Independent Digital Healthcare Agency in U.S. 2nd Year in a Row 2Telik Announces First Quarter 2011 Financial Results 2Telik Announces First Quarter 2011 Financial Results 3
(Date:2/26/2015)... February 26, 2015 Software and ... FDA’s Position and Best Practices for Compliance, **Presented ... Bethesda, MD, http://www.fdanews.com/SoftwareAndCybersecurity , This workshop ... — has been specifically designed to provide attendees ... effectively assure medical device software safety. , In ...
(Date:2/26/2015)... Arbor, Michigan (PRWEB) February 26, 2015 ... different procedures that accomplish two different things—but they can ... When blending a tummy tuck with liposuction, Michigan’s Dr. ... ,” which he's seen grow in popularity by 50 ... , Why are more patients seeking to combine the ...
(Date:2/26/2015)... 2015 Eating disorders are serious, ... adulthood. In response to emerging research regarding eating ... of National Eating Disorders Awareness Week, the Society ... evidence-based recommendations for the medical management of restrictive ... a new approach to assessing the degree of ...
(Date:2/26/2015)... Epsom, UK (PRWEB) February 26, 2015 ... placed 56th in The Sunday Times “100 Best Small Companies ... time Kantar Health UK has been included on the list, ... “We have a fantastic team here at Kantar Health UK, ... and competitive list,” Kantar Health UK CFO Mark Hinton-Jones said. ...
(Date:2/26/2015)... Body Well Therapy, a multi-regional provider of ... high quality mobile massage services to individuals and ... the United States. The company has experienced steady growth since ... it sets its sights on additional major market expansion of ... , “We’ve come a long way since our founding in ...
Breaking Medicine News(10 mins):Health News:FDAnews New Workshop — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, April 14-15 2Health News:FDAnews New Workshop — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, April 14-15 3Health News:FDAnews New Workshop — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, April 14-15 4Health News:Dr. Pramit Malhotra Reports a Rise in Patients Combining Liposuction and Tummy Tuck in Michigan, Citing the “Power LipoTuck” 2Health News:Dr. Pramit Malhotra Reports a Rise in Patients Combining Liposuction and Tummy Tuck in Michigan, Citing the “Power LipoTuck” 3Health News:SAHM: Medical Providers Have Vital Lead Role in Diagnosing, Treating Restrictive Eating Disorders in Adolescents and Young Adults 2Health News:SAHM: Medical Providers Have Vital Lead Role in Diagnosing, Treating Restrictive Eating Disorders in Adolescents and Young Adults 3Health News:Kantar Health UK Named One of The Sunday Times 100 Best Small Companies to Work For 2Health News:Body Well Therapy Celebrates 10 Years of Quality Mobile Massage Services 2Health News:Body Well Therapy Celebrates 10 Years of Quality Mobile Massage Services 3
... at the University of California, San Diego School of ... biomarker and therapeutic target for pancreatic cancer, an often-fatal ... for early detection or therapeutic intervention. The paper ... . Pancreatic ductal adenocarcinoma, or PDAC, is the ...
... University] A new study led by Brown University ... long assumed to help bedridden dementia patients stave off ... sores more likely to develop or not improve. ... advanced dementia appears in the May 14 edition of ...
... , MONDAY, May 14 (HealthDay News) -- People ... sudden cardiac arrest than those in the general population, a ... people with well-controlled HIV, according to researchers from the University ... referred to as sudden cardiac death, the heart suddenly and ...
... , , , , , ... , , AUDIO: ... the cancer... , Click here for more information. ... , , , , , ...
... By Kathleen Doheny HealthDay Reporter , ... help relieve muscle tightness, called spasticity, and pain in ... "Spasticity is a major problem [in multiple sclerosis]," ... University of California, San Diego Multiple Sclerosis Center. "People ...
... -- The multiple sclerosis drug Gilenya (fingolimod) should not ... heart conditions or stroke, or those taking certain medications ... and Drug Administration safety announcement issued Monday. The ... a patient who died within 24 hours after receiving ...
Cached Medicine News:Health News:Early biomarker for pancreatic cancer identified 2Health News:Gastric feeding tubes may raise pressure ulcer risk 2Health News:Gastric feeding tubes may raise pressure ulcer risk 3Health News:People With HIV at Higher Odds of Sudden Cardiac Death 2Health News:Genetic test identifies eye cancer tumors likely to spread 2Health News:Genetic test identifies eye cancer tumors likely to spread 3Health News:Genetic test identifies eye cancer tumors likely to spread 4Health News:Genetic test identifies eye cancer tumors likely to spread 5Health News:Pot Might Help Ease Multiple Sclerosis Symptoms 2Health News:Pot Might Help Ease Multiple Sclerosis Symptoms 3Health News:FDA Issues Multiple Sclerosis Drug Alert 2
Multispot HIV-1/HIV-2 is a rapid indirect EIA using recombinant and peptide antigens for simultaneous detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies in human serum or plasma....
Bio-Rad's Genetic Systems™ HBsAg EIA 3.0 screening and confirmatory assays offer outstanding sensitivity and early detection of HBV infection, helping to meet your testing criteria....
The most compact revolutionary innovation in hematology. 3 Part DIFF + CRP measurement on whole blood....
... Evolis™ is a self contained microplate ... based EIA assays. The system is dedicated ... encountered in todays busy laboratory. The system ... of EIA assays that satisfy their microplate ...
Medicine Products: